المؤلفون: Yıldız, Oğuzhan¹ dr.oguzhan@outlook.com, Gürbüz, Ali Fuat¹, Karakurt Eryılmaz, Melek¹, Araz, Murat¹, Aykut, Talat¹, Şahin, Özlem², Büyükboyacı, Naciye Hilal³, Çelik, Zeliha³, Artaç, Mehmet¹

المصدر: Journal of Oncology Pharmacy Practice. Jan2025, Vol. 31 Issue 1, p168-171. 4p.

مصطلحات موضوعية: *HYDROXYCHLOROQUINE, *DOCETAXEL, *TRASTUZUMAB, *LYMPHADENECTOMY, *BREAST tumors, *SYSTEMIC lupus erythematosus, *POSITRON emission tomography computed tomography, *TREATMENT effectiveness, *METASTASIS, *MONOCLONAL antibodies, *ZOLEDRONIC acid, *MASTECTOMY

المؤلفون: McElree, Ian M.¹ (AUTHOR) ian-mcelree@uiowa.edu, Packiam, Vignesh T.² (AUTHOR) vignesh.packiam@rutgers.edu, Steinberg, Ryan L.³ (AUTHOR) ryan-steinberg@uiowa.edu, Hougen, Helen Y.³ (AUTHOR) helen-hougen@uiowa.edu, Abou Chakra, Mohamad³ (AUTHOR) mohamad-abouchakra@uiowa.edu, Mott, Sarah L.⁴ (AUTHOR) sarah-mott@uiowa.edu, O'Donnell, Michael A.^3,4 (AUTHOR) michael-odonnell@uiowa.edu

المصدر: Cancers. Dec2024, Vol. 16 Issue 24, p4126. 12p.

مصطلحات موضوعية: *DOCETAXEL, *CANCER relapse, *RESEARCH funding, *MITOMYCINS, *TREATMENT effectiveness, *DESCRIPTIVE statistics, *TRANSITIONAL cell carcinoma, *ODDS ratio, *KAPLAN-Meier estimator, *DOXORUBICIN, *GEMCITABINE, *DATA analysis software, *CONFIDENCE intervals, BLADDER tumors

المؤلفون: Collette, Kaylyn^1,2 kaylyn.collette@uky.edu, Perkey, Cassandra L.³, Adams, Val⁴, Shelton, Brent J.², Corum, Lauren S.², Butts, Allison^1,2

المصدر: Journal of Oncology Pharmacy Practice. Dec2024, Vol. 30 Issue 8, p1335-1342. 8p.

مصطلحات موضوعية: *THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *TRASTUZUMAB, *BODY mass index, *HORMONE receptor positive breast cancer, *BREAST tumors, *PATHOLOGIC complete response, *CARBOPLATIN, *RETROSPECTIVE studies, *CANCER patients, *DESCRIPTIVE statistics, *TREATMENT effectiveness, *MONOCLONAL antibodies, *CANCER chemotherapy, *COMBINED modality therapy, *MEDICAL records, *ACQUISITION of data, *TREATMENT delay (Medicine), *EPIDERMAL growth factor receptors

مصطلحات جغرافية: UNITED Kingdom

المؤلفون: Wilson, Isabella^1,2 (AUTHOR) Isabellawilson@outlook.com.au, Strach, Madeleine^1,2 (AUTHOR), Bhadri, Vivek^1,2 (AUTHOR), Harrison, Michelle¹ (AUTHOR), Tang, Whiter¹ (AUTHOR), Grimison, Peter^1,2 (AUTHOR)

المصدر: Asia Pacific Journal of Clinical Oncology. Nov2024, p1. 6p. 3 Illustrations.

مصطلحات موضوعية: *SARCOMA, *DOCETAXEL, *OVERALL survival, *GEMCITABINE, *SURVIVAL analysis (Biometry)

المؤلفون: Xu, Jianyu¹ (AUTHOR) aladdine@163.com, Zhu, Ying¹ (AUTHOR), Liu, Qian² (AUTHOR), Xu, Chenchang³ (AUTHOR), Wang, Wenjuan⁴ (AUTHOR), Sun, Jiantong¹ (AUTHOR), Ding, Xinyuan¹ (AUTHOR), Liu, Biao² (AUTHOR), Chen, Lei³ (AUTHOR)

المصدر: Oncology. Nov2024, p1-16. 16p. 6 Illustrations.

مصطلحات موضوعية: *IMMUNE checkpoint proteins, *DOCETAXEL, *CELL division, *TUMOR growth, *CANCER invasiveness

المؤلفون: Kwon, Whi-An¹ (AUTHOR) kein917@hanyang.ac.kr, Song, Yong Sang² (AUTHOR), Lee, Min-Kyung³ (AUTHOR) kein917@hanyang.ac.kr

المصدر: Cancers. Sep2024, Vol. 16 Issue 18, p3187. 27p.

مصطلحات موضوعية: *CASTRATION-resistant prostate cancer, *DOCETAXEL, *ANTINEOPLASTIC agents, *TUMOR markers, *TREATMENT effectiveness, *METASTASIS, *CANCER chemotherapy, *INDIVIDUALIZED medicine, *QUALITY assurance, *ANDROGEN receptors, *OVERALL survival

المؤلفون: Low, Kaan¹ (AUTHOR), Foulkes, Paola¹ (AUTHOR), Hills, Frank¹ (AUTHOR), Roberts, Helen C.¹ (AUTHOR), Stordal, Britta¹ (AUTHOR) b.stordal@mdx.ac.uk

المصدر: Cancer Medicine. Sep2024, Vol. 13 Issue 18, p1-13. 13p.

مصطلحات موضوعية: *CLINICAL trials, *DOCETAXEL, *CISPLATIN, *METHOTREXATE, *COMBINATION drug therapy

المؤلفون: Wenzel, Mike¹ mikewenzel91@aol.com, Hoeh, Benedikt¹, Wagner, Nele¹, Koll, Florestan¹, Siech, Carolin¹, Humke, Clara¹, Steuber, Thomas², Graefen, Markus², Tilki, Derya^2,3,4, Kluth, Luis¹, Traumann, Miriam¹, Banek, Séverine¹, Chun, Felix K. H.¹, Mandel, Philipp^1,2

المصدر: Journal of the American Geriatrics Society. Sep2024, Vol. 72 Issue 9, p2700-2708. 9p.

مصطلحات موضوعية: *THERAPEUTIC use of antineoplastic agents, *DOCETAXEL, *ACADEMIC medical centers, *T-test (Statistics), *KRUSKAL-Wallis Test, *LIFE expectancy, *PROSTATE tumors, *TREATMENT effectiveness, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *CHI-squared test, *MULTIVARIATE analysis, *METASTASIS, *KAPLAN-Meier estimator, *CANCER chemotherapy, *ANDROGEN receptors, *OVERALL survival, *PROPORTIONAL hazards models, *REGRESSION analysis, *OLD age

مصطلحات جغرافية: GERMANY

المؤلفون: Seagen Inc.

المصدر: An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12.

Other URLs: https://www.clinicaltrials.astellas.com/transparency/

المصدر: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: The Registry to Observe Clinical Outcomes of Patients With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

المصدر: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4.

Other URLs: http://www.amgen.com/datasharing

المؤلفون: GOG Foundation

المصدر: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Mori KM, Giuliano PD, Lopez KL, King MM, Bohart R, Goldstein BH. Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient. Anticancer Drugs. 2019 Nov;30(10):1064-1066. doi: 10.1097/CAD.0000000000000836.
Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, Holloway RW. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021 Dec;163(3):481-489. doi: 10.1016/j.ygyno.2021.10.069. Epub 2021 Oct 20. Erratum In: Gynecol Oncol. 2022 May;165(2):401. doi: 10.1016/j.ygyno.2022.02.014.
Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, Fitzsimmons CK, Kennard JA, King M, LeBlanc J, Lopez K, Manyam M, McKenzie ND, Mori KM, Stephens AJ, Sarfraz A. 2020 International Gynecologic Cancer Society, Oral Plenary Session presentation of VIRO-15 Phase 2 Trial Data, Robert Holloway, AdventHealth Cancer Institute, Orlando, FL. International Journal of Gynecologic Cancer 2020;30:A9-A10
Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007.

المؤلفون: BeiGene

المصدر: A Phase 1, Open-Label, Dose Escalation and Expansion Study of Mavrostobart (PT199) Administered Alone in Adult Patients with Advanced Solid TuMORs, in CombiNation with a Checkpoint INhibitor TreatinG Wild-type Non-Small Cell Lung Cancer, or in Combination with ChemoTherapy for Metastatic or Advanced PAncreatic Ductal AdenocaRcinoma (MORNINGSTAR)

المؤلفون: NRG Oncology

المصدر: Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

المصدر: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

Other URLs: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html

المؤلفون: Regeneron Pharmaceuticals

المصدر: Multicenter Randomized Phase II Trial of Neoadjuvant Radioimmunotherapy Versus Chemoimmunotherapy in Patients With Clinical Stages IB-III (N2) Non-small Cell Lung Cancer

المصدر: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Other URLs: https://trials.arcusbio.com/our-transparency-policy

المصدر: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer